Biocon Reports Strong Financial Results for Q4FY26 and FY26

Biocon Reports Strong Financial Results for Q4FY26 and FY26​

Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fourth quarter (Q4FY26) and the financial year (FY26) ending March 31, 2026. The company reported significant growth across its key segments, highlighting the successful integration of its biosimilars and generics businesses.

Financial Highlights for FY26​

Biocon's consolidated financials showed substantial increases year-over-year. For the full fiscal year 2026, the company reported:

• Total Income: Rs 17,270 Crore, up 14% year-on-year.
• EBITDA: Rs 3,798 Crore, up 25% year-on-year, achieving a 22% EBITDA margin.
• Net Profit (before exceptional items): Rs 436 Crore, up 323% year-on-year.

The company also highlighted its strong performance in Q4FY26:


*Note: Growth figures are adjusted for one-time generic lenalidomide sales in Q4FY25.

Segmental Revenue Contribution​

The company's revenue stream demonstrated varied growth across its core units. Total revenue from operations for FY26 was Rs 16,927 Crore, driven by the following segments:


The Biosimilars segment remained a core growth driver, reporting Q4FY26 revenue from operations at Rs 2,756 crore, up 12% year-on-year. The Generics segment saw revenue from operations at Rs 847 crore in Q4FY26, up 13% year-on-year.

Management Commentary and Strategy​

Biocon’s Executive Chairperson, Kiran Mazumdar-Shaw, commented that the company closed FY26 on a strong note, delivering margin expansion along with 13% YoY growth in operating revenue. She noted that the integration of the biosimilars business with generics formulations and APIs has created a unified biopharma entity with a stronger balance sheet and more global commercial footprint.

The CEO & Managing Director, Shreehas Tambe, remarked that FY26 was a pivotal year marked by the successful integration of the biosimilars and generics business. He stated that the overall EBITDA margin expansion was driven by an improved product mix and operational excellence.

Regarding Syngene International Limited, Peter Bains, CEO & Managing Director, noted that the Research Services revenue grew 3% for FY26, with an EBITDA margin of 25%, remaining in line with revised guidance.

Financial Structure and Board Updates​

In addition to the operational results, the Board of Directors recommended a final dividend of Re. 0.50 per share for the financial year ending March 31, 2026.

The company also updated its leadership team, with Shreehas Tambe taking charge as CEO & Managing Director of Biocon Limited on April 1, 2026, and Kedar Upadhye appointed as Chief Financial Officer.

The consolidated balance sheet as of March 31, 2026, showed a total assets of Rs 63,651 Crore, compared to Rs 58,797 Crore on March 31, 2025. Total equity and liabilities also stood at Rs 63,651 Crore.

BIOCON Stock Price Movement​

On Thursday, Biocon Limited shares edged higher, closing at ₹382.25 after gaining 0.45%. Trading volume hit 5.23 million shares, with the stock ranging between a low of ₹379.6 and a high of ₹386.3.